Fakeeh Care Group Reports 1H26 Revenue of SAR 1,523 million, Up 6% Year on Year Excluding 2025's non-recurring Hajj Contract; New Business Revenue Nearly Doubles as DSFH Riyadh and DSFH Madinah Maintain Their Steep Growth Trajectories

The Group advances its hub-and-spoke expansion strategy with completion of the acquisition of Dr. Mohammed AlFagih Hospital in Riyadh and the inauguration of DSFMC AlAwali, its Medical Center in Makkah

2Q-2026 Highlights[1]

Revenue	SAR 799 MN	▼ 2% YoY; ▲ 8% exc. Hajj
Gross Profit	SAR 175 MN	▼ 3% YoY / 22% margin
Total Patients Served[2]	485,611	▲ 4% YoY
EBITDA[3]	SAR 123 MN	▼ 5% YoY / 15% margin
Attributable Net Profit	SAR 58 MN	▼ 29% YoY
Earnings Per Share	SAR 0.25	▼ 29% YoY
New Business Revenue[4]	SAR 132 MN	▲ 93% YoY
New Business Patients[2]	90,086	▲ 68% YoY

1H-2026 Highlights[1]

Revenue	SAR 1,523 MN	▲ 0.7% YoY; ▲ 6% exc.Hajj
Gross Profit	SAR 315 MN	▼ 12% YoY / 21% margin
Total Patients Served[2]	924,308	▲ 3% YoY
EBITDA[3]	SAR 219 MN	▼ 12% YoY / 14% margin
Attributable Net Profit	SAR 96 MN	▼ 38% YoY
Earnings Per Share	SAR 0.42	▼ 38% YoY
New Business Revenue[4]	SAR 238 MN	▲ 86% YoY
New Business Patients[2]	164,366	▲ 66% YoY

Jeddah, KSA, 06 August 2026: Dr Soliman Abdel Kader Fakeeh Hospital Company and its Subsidiaries ("Fakeeh Care Group", "FCG", "Fakeeh Care", the "Company" or the "Group"), a leading fully integrated academic healthcare provider listed on TASI (SYMBOL: 4017 and ISIN code SA562GSHUOH7), announces today its financial results[1] for the period ended 30 June 2026.

Key Financial & Operational Highlights

- **Underlying Revenue Growth of 6%:** Group revenue was SAR 799 million in 2Q26 and SAR 1,523 million in 1H26, from SAR 1,513 million in 1H25. Adjusting for the non-recurring 2Q25 Hajj contract, revenue grew 7.6% year on year in the quarter and 5.5% year to date, reflecting the underlying growth trajectory across the Group's operating platform.

---

[1] *In accordance with the International Financial Reporting Standards (IFRS).*
[2] *The Group calculates Patients Served as the total of outpatients, inpatients, and home healthcare cases served during the period.*
[3] *The Group calculates EBITDA as Earnings Before Interest and Tax (EBIT) plus depreciation and amortization, and non-cash Long-term Incentive Plan (LTIP).*
[4] *The Group calculates New Business by excluding DSFH Riyadh and DSFH Madinah's financial and operational figures from the consolidation and presents them as New Business performance.*

- **Patients Served Growth Led by Higher-Acuity Care:** The Group served 485,611 patients in 2Q26 and 924,308 in 1H26, up 4.4% and 2.8% year on year respectively. Inpatient admissions rose 15.7% and surgical procedures grew 26.2% in the quarter, reflecting the continued shift in case-mix toward tertiary and complex care across the network.

- **New Business Nearly Doubles; Now One-Sixth of Group Revenue:** New Business, comprising DSFH Riyadh and DSFH Madinah, generated SAR 132 million in revenue in 2Q26, up 93.5% year on year, and SAR 238 million in 1H26, up 86.5%. Collectively, they represented 15.6% of consolidated revenue year to date, from 8.4% a year earlier, as DSFH Riyadh deepened its service-line breadth and DSFH Madinah contributed a full period of operations against a partial-period prior-year base.

- **New Business Patients Served Scale up, supported by the brand's value:** DSFH Riyadh and DSFH Madinah together served 164,366 patients year to date, up 66% year on year, with inpatient admissions up 111% to 7,659 and surgical procedures up 115% during the period, as both hospitals continued to ramp up their utilization rates.

- **As New Business scaled up, it absorbed headwinds in mature business:** Group EBITDA was SAR 122.7 million in 2Q26 at a 15.4% margin, from SAR 129.1 million and 15.9% a year earlier, due to M&A related expenses. The New Business narrowed its combined EBITDA loss by roughly SAR 23 million year on year, and for the first time generated positive gross profit at the cohort level, an improvement that largely absorbed the lower contribution of higher-margin Home Healthcare, the repricing of the Group's O&M contracts in NEOM, and competition in Jeddah.

- **Balance Sheet and Liquidity remained solid:** The Group held total liquid funds of SAR 657 million at period-end, comprising SAR 357 million of cash and SAR 300 million invested in government sukuk. The Group was in a net debt position of SAR 69 million on a cash-plus-sukuk basis, with net debt to LTM EBITDA at 0.15 times. Capex and investments amounted to SAR 172 million year to date, as the Group continued to fund its network expansion.

- **Hub-and-Spoke Expansion is Progressing:** DSFMC Alawali is in its soft-opening phase, while DSFMC North Obhur has completed construction and is progressing ahead of its planned soft opening in the coming months, and DSFMC Al Zahra completion is tentatively planned for December 2026.

- **Completion of the Acquisition of Dr. Mohammed Bin Rashid Al Fagih & Partners Company:** Subsequent to period-end, on 20 July 2026, the Group completed the acquisition of 100% of Dr. Mohammed Bin Rashid Al Fagih & Partners Company, a 350-bed multi-specialty general hospital in Riyadh, for a total cash consideration of SAR 1.6 billion. The acquisition complements DSFH Riyadh to form a 535-bed two-site cluster in the capital and broadens the Group's payor mix.

- **DSFH Jeddah Delivers Saudi Arabia's First Private-Sector Autologous Hematopoietic Stem Cell Transplant**: DSFH Jeddah performed the first autologous stem cell transplant in Saudi Arabia's private healthcare sector, treating a 55-year-old patient diagnosed with multiple myeloma. The milestone deepens the Group's tertiary and quaternary service-line breadth in hematology and oncology, an area central to its higher-acuity case-mix strategy, and reinforces DSFH Jeddah's position as a leading provider of advanced, complex care within the Kingdom's private sector.

- **Kingdom-Leading Recognition in Patient Safety:** DSFH Jeddah became the first and only hospital in Saudi Arabia to achieve the Gold Level Patient Safety Standards Certificate from the Saudi Patient Safety Center in the program's first cycle, while DSFH Riyadh achieved the Silver Level, the highest-ranked hospital among those recognized in Riyadh.

Commenting on the Group's performance, FCG's President Dr. Mazen Soliman Fakeeh said:

"Year to date in 2026, Fakeeh Care Group's revenue reached SAR 1,523 million, growing by 6% year on year excluding the prior-year Hajj contract. This growth was driven by our New Business, where DSFH Riyadh and DSFH Madinah nearly doubled their combined revenue and, for the first time, together covered their direct costs. Year to date, the Group served 3% more outpatients and 14% more inpatients and conducted 22% more surgical procedures than in the first six months of 2025, reflecting our core strength in higher-acuity and complex care.

Our earnings in the period reflected strong growth from New Business, moderated by a number of transitional pressures across the Mature Business. Our integrated care model, serving patients from infancy through old age across primary and tertiary facilities and in their homes, continued to demonstrate its resilience. We also continued to invest in the digital infrastructure supporting our value-based care model and improving operating efficiency across Fakeeh Care Group. We believe this diversified platform is well positioned to sustain our competitive advantage and support our participation in the sector's forthcoming privatization opportunities.

Subsequent to the quarter, on the 20th of July, we completed the acquisition of Dr. Mohammed Bin Rashid Al Fagih & Partners Company, a 350-bed multi-specialty hospital in Riyadh. This defining step adds proven scale in a high-density catchment, complements DSFH Riyadh to form a 535-bed cluster in the Kingdom's capital, and broadens our payor mix. Together with the medical center openings scheduled for this year, starting this month with Al Awaili in Makkah, reflects an expansion model that combines both, organic build-out with disciplined acquisitions.

Looking ahead, our priorities are to drive utilization across the New Business toward breakeven, maintain the standards that define the Group, integrate the newly acquired Riyadh hospital effectively into our ecosystem, and advance our network expansion. With a resilient core, a scalable model proven across geographies, and a deepening role in the Kingdom's healthcare transformation, Fakeeh Care Group is well positioned to create enduring value for patients, staff, students, shareholders, and the broader community."

Strategic Developments

- **Completion of the Acquisition of Dr. Mohammed Fagih Hospital:** On the 20th of July 2026, the Group completed the acquisition of 100% of the share capital of Dr. Mohammed Bin Rashid Al Fagih & Partners Company, a 350-bed multi-specialty general hospital in Central-East Riyadh, for a total cash consideration of SAR 1.6 billion. Starting from 3Q26 the hospital's financial and operational performance will be consolidated.

  The acquisition combines with DSFH Riyadh's 185-bed capacity to create a 535-bed two-site cluster and diversifies the Group's payor and patient mix in Riyadh by adding exposure to Network 6 / Class B insurance, complementing the Group's existing A Class / VIP and high-tier insurance positioning. Over time, the combination is expected to generate operational efficiencies, cost synergies, and enhanced revenue opportunities across the Group's network.



- **Saudi Arabia's First Private-Sector Autologous Hematopoietic Stem Cell Transplant**: DSFH Jeddah performed the first autologous stem cell transplant in Saudi Arabia's private healthcare sector, treating a 55-year-old patient diagnosed with multiple myeloma.

  The procedure marks the launch of the hospital's Stem Cell Transplantation and Cellular Therapy Program and demonstrates its readiness to deliver highly specialized treatments in line with leading global clinical standards. The milestone deepens the Group's tertiary and quaternary service-line breadth in hematology and oncology, an area central to its higher-acuity case-mix strategy, and reinforces DSFH Jeddah's position as a leading provider of advanced, complex care within the Kingdom's private sector.


- **Patient Safety and Organizational Excellence; Kingdom-Leading Recognition Across the Network:** Fakeeh Care Group continues to extend its clinical governance and quality leadership with recognition from the Saudi Patient Safety Center (SPSC) at two of its hospitals.

  DSFH Jeddah became the first and only hospital in Saudi Arabia to achieve the Gold Level Patient Safety Standards Certificate in the program's first cycle, while DSFH Riyadh achieved the Silver Level, becoming one of only two hospitals in the Kingdom to attain that level in the first cycle.

  The SPSC program evaluates providers' adherence to safe clinical practices, medication safety, infection prevention and control, risk management, and continuous quality improvement.

Total Operational Beds

(Beds/Occupancy %)



Total Patients Served



Outpatient Visits

('000)



Inpatient Admissions

('000)



Surgical Procedures



Operational Review

Fakeeh Care Group served 485,611 patients in 2Q26, up 4.4% year on year, and 924,308 patients in 1H26, up 2.8% year on year. Growth was led by higher-acuity care where inpatient admissions rose 15.7% to 14,443 in 2Q26 and 13.6% to 26,921 in 1H26, while surgical procedures grew 26.2% in 2Q26 and 21.9% in 1H26.

The continued progression towards tertiary and complex cases reflects the ongoing integration of higher-complexity service lines across the Group's New Business alongside sustained sub-specialty depth in its Mature Business.

The Group operated 545 beds across its three hospitals as of 2Q26. Consolidated inpatient utilization in 2Q26 averaged 75%, reflecting the additional capacity brought on at DSFH Madinah. Within the New Business, DSFH Riyadh utilization rose to 79% in 2Q26 on a continued growth in patients served against a stable base of 102 beds, while DSFH Madinah reached 59% by operating 70 beds in 2Q26 against 48 a year earlier shortly after inauguration in May 2025. In mature business, Jeddah Hospital maintained in 2Q26 an 82% utilization rate on 373 beds.

The Mature Business, comprising the Group's Jeddah-based hospital, and medical centers together with Home Healthcare, served 395,525 patients in 2Q26 and 759,942 patients in 1H26. Patients served in Home Healthcare were lower this year, as volumes reflect a shift by strategic payors toward delivering home healthcare in-house, and accordingly management is in concrete discussions with other payors aiming to resume the business line’s previous growth trajectory.

The New Business, comprising DSFH Riyadh and DSFH Madinah, served 90,086 patients in 2Q26 and 164,366 patients in 1H26, up 68% and 66% year on year respectively. Growth was further fueled by higher-acuity activity, where inpatient admissions grew by 111% to 7,659 in 1H26, while surgical procedures grew by 115% in 1H26, as both hospitals deepened their service-line breadth and DSFH Madinah contributed a full period of operations against a partial-period in the prior-year’s base.

That said, is worth noting that DSFH Madinah's monthly run-rate rose to approximately 9,400 patients in 2Q26, from approximately 7,000 in 1Q26. The Hospital after its opening in May 2025, has expanded its offering across all specialties including Oncology and Cardiology, fueling its ICU occupancy to over 80%. As a result of this strong demand, management has increased the hospital’s number of operational beds to 101 as of 3Q26.

Group Revenue

(SAR mn)



Total Revenue Breakdown



Healthcare Revenue Breakdown



Cost of Revenue Breakdown

(SAR mn / % of revenue)



Financial Review

Group revenue was SAR 799 million in 2Q26 and SAR 1,523 million in 1H26. Adjusting for the non-recurring 2Q25 Hajj contract, revenue grew 7.6% year on year in the quarter and 5.5% in the half, reflecting the underlying growth trajectory across the Group's operating platform. Case-mix continued to shift toward higher-acuity care across the Group's facilities, inpatient revenue grew 13.0% in 2Q26 and 10.9% in 1H26, outpacing outpatient growth of 9.8% and 4.8%, considering DSFMC Medical Fakeeh's contract change. Consistent with the throughput trends described in the operational review, average revenue per patient served grew by 3% in 1H26 versus 1H25 as the Group continues to deepen its tertiary, quaternary, and complex-care service offerings.

New Business was a key driver of consolidated revenue growth. Revenue from DSFH Riyadh and DSFH Madinah nearly doubled to SAR 132.1 million in 2Q26 and grew 86.5% to SAR 237.8 million in 1H26, growing its share of consolidated revenue to 15.6% over the first six months, from 8.4% a year earlier. Both hospitals continued to scale in line with the Group's expansion strategy, with DSFH Madinah spearheading the growth as it contributes a full period of operations against a partial period in the prior-year base. As the New Business sustains this trajectory, it is expected to further grow its contribution to consolidated revenue while broadening the Group's revenue sources geographically over the coming quarters.

Mature Business revenue was SAR 666.8 million in 2Q26 and SAR 1,285.2 million in 1H26, 1.1% and 2.3% lower year on year respectively after excluding the 2025 Hajj contract. The decline was attributed to Home Healthcare, the O&M contracts and increased competition in Jeddah. Home Healthcare was under pressure as strategic payors have progressively shifted from outsourcing home healthcare to delivering it in-house. This dynamic drove Home Healthcare revenue down 45.5% year to date, while discussions with other strategic payors continued to progress. The Group's O&M contracts in NEOM generated a lower revenue compared with the prior-year period, reflecting the reduced scale of activity across NEOM and the resulting reduction in healthcare service requirements.

Operating Costs Analysis

Cost of revenue was broadly flat in 2Q26 at SAR 623.9 million, holding gross profit at SAR 175.0 million and a 21.9% margin, against SAR 180.6 million and 22.2% in 2Q25. For the half year, cost of revenue rose to SAR 1,208.2 million, with gross profit of SAR 314.9 million at a 20.7% margin, from SAR 356.8 million and 23.6% in 1H25. The revenue impact on the margin was contained by the Group's continued cost discipline, and the New Business beginning to cover its direct costs.

Gross Profit
(SAR mn / Margin %)



On a Group level, direct salaries and related benefits fell to 39.9% of revenue in 2Q26, from 44.2% a year earlier, and held flat in 1H26 compared to 1H25, even as New Business added operational capacity over the past twelve months. This achievement was as a result of the Group's cost-containment measures coupled with New Business revenue growth. The savings from salaries softened the rise in materials and consumables, which read 25.3% of revenue in 2Q26 from 21.7% in 2Q25, and 24.4% in 1H26 versus 22.6% in 1H25. This rise reflected regional supply-chain cost pressures coupled with changes in the Group's case mix. That said, the increase in the "others" expenses of cost of revenue was driven by DSFH Madinah's higher depreciation expense during the period as well as new leases.

Mature Business gross margin eased to 26.1% in 2Q26 from 27.1% a year earlier, and to 25.4% in 1H26 from 27.9%. This primarily reflected the lower contribution from higher-margin Home Healthcare services, the input-cost inflation and intensifying competition in Jeddah.

The New Business, DSFH Riyadh and DSFH Madinah together, generated a gross profit of approximately SAR 0.7 million in 2Q26, marking the first quarter in which they covered their direct costs. This compares with a gross loss of SAR 20.7 million in 2Q25, largely attributable to DSFH Madinah following its opening in May 2025. The gap between the Mature Business margin and the overall Group's margin still reflects ramp up impact ahead of full occupancy, but it is closing steadily as New Business revenue continues to build against its cost base. Together, the Group's cost discipline and the New Business's progress alleviated the Mature Business headwinds, holding the consolidated gross margin broadly flat in 2Q26.

SG&A
(SAR mn / SG&A to Revenue %)



EBITDA
(SAR mn / Margin %)



Operating Profitability analysis

Group EBITDA tracked the movement in gross profit at the consolidated level, cushioned by continued cost discipline and New Business's narrowing losses. Selling, general and administrative expenses were 12.5% of revenue in the quarter and 12.6% in the half, slightly higher year on year considering New Business added capacity and its associated depreciation, as well as M&A related expenses. That said, the support base continues to benefit from the Group's centralization and outsourcing initiatives, which aim to protect gross-profit gains and enable them to carry through to operational profitability.

The Mature Business EBITDA margin was 20% in 2Q26 and in 1H26, from 22.0% and 22.6% a year earlier. The year-on-year movement reflects the revenue dynamics already highlighted. Against this, the New Business narrowed its combined EBITDA loss by SAR 23 million in 2Q26 and in 1H26, as DSFH Riyadh and DSFH Madinah sustained their steep growth trajectories. As utilization continues to build across both hospitals, that drag should keep narrowing.







*Cash as of Dec 2025 & Jun 2026 include Sukuk amounting to SAR 298.1mn & SAR 300.1mn respectively



Net Profit

Net profit in 2Q26 grew from 1Q26 to SAR 54.1million which drove 1H26 Net Profit to SAR 80.3 million as almost all business expanded post the first quarter's seasonality. Similarly, profits attributable to shareholders were SAR 57.9 million in 2Q26 and SAR 96.3 million in 1H26, with earnings per share of SAR 0.25 and SAR 0.42 respectively.

The decline in net profit was driven by lower revenue contributions from the Mature Business and Home Healthcare, the repricing of the Group's O&M contracts, one-off transaction costs related to the acquisition of Dr. Mohammed AlFagih Hospital, and higher depreciation and amortization at DSFH Madinah, which operated for the full period compared with only two months in the prior-year period.

Nevertheless, net profit benefited from improved efficiency across New Business. This was achieved despite SAR 5.3 million pre-operating expenses related to DSFMC Al Awali, the Group's newest medical center in Makkah, as well as two new land leases associated with the planned medical college in Madinah and the Jizan Hospital project.

Net finance costs rose to SAR 9.6 million in 2Q26 from SAR 4.6 million a year earlier, and to SAR 20.2 million in 1H26 from SAR 6.8 million, reflecting the higher average debt balances as well as the interest on DSFH Madinah borrowings previously treated as pre-operating and were accordingly capitalized.

Balance Sheet, Liquidity & Capital Deployment

Liquidity headroom remained strong, where cash and cash equivalents stood at SAR 357 million, coupled with SAR 300 million invested in government sukuk, taking total liquid funds to SAR 657 million, preserving flexibility to support the Group's investment cycle.

Capex and investments amounted to SAR 172 million year to date, as the Group continued to fund its network expansion, with DSFMC Alawali becoming operational and DSFMC North Obhur progressing through testing and commissioning. Total loans (short- and long-term) increased to SAR 726 million in 1H26 (SAR 632 million in FY25), while the Group moved to a net debt position of SAR 69 million on a cash-plus-sukuk basis, retaining sufficient liquidity headroom to support the Group's growth initiatives. Accordingly, on a cash-plus-sukuk basis, net debt to LTM EBITDA reads 0.15 times, preserving balance-sheet flexibility for the ongoing investment cycle.

Building on the strong liquidity position, the Group secured SAR 2.2 billion of new credit facilities from local banks to fund its growth projects including the acquisition of Dr Mohammed Alfagih Hospital that was finalized on July 20th 2026, for a total consideration of SAR 1.6 billion.

– Ends –

About Fakeeh Care Group

Established in 1978 by the late Dr. Soliman Fakeeh, the Fakeeh Care Group stands as a pioneer in integrated healthcare services in Saudi Arabia. Our comprehensive healthcare offering includes our core healthcare services ranging from ambulatory care to secondary and tertiary care, supported by Emergency Medical Services and Fakeeh Home Healthcare. Additionally, our offerings are enhanced by our industry-leading academic healthcare programs. Building on a strong track record of growth in our home city of Jeddah, the Group embarked on a Kingdom-wide expansion strategy to bring our well proven hub-and-spoke model and medical support services to major cities across Saudi Arabia.

In June 2024, Fakeeh Care Group successfully concluded its initial public offering (IPO) on the Tadawul. The IPO raised gross proceeds of SAR 2.9 billion (US$ 764 million) for the Company and the Selling Shareholders of which SAR 1.7 billion will be used to support and accelerate the Group's growth strategy.

For further information, please contact:

Mr Waleed Hamed
Investments & Investor Relations Director
Email: wahamed@fakeeh.care

Mr Panagiotis (Panos) Chatziantoniou
Vice President, Group Investments and Treasury
Email: investors@fakeeh.care

Forward-looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "anticipates", "assumes", "believes", "could", "estimates", "expects", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would", or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding the Company's business and management, its future growth or profitability and general economic and regulatory conditions and other matters affecting it.

These forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its subsidiaries and its investments, including, among other things, the development of its business, financial condition, prospects, growth, strategies, as well as the trends in the industry and macroeconomic developments in the Kingdom of Saudi Arabia. Many of these risks and uncertainties relate to factors that are beyond the Company's control or accurate estimation, such as future market conditions, currency fluctuations, the behaviour of other market participants, the actions of regulators and any changes in applicable laws or regulations or government policies. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not otherwise occur and past performance shall not be taken as a guarantee of future results. No representation or warranty is made pertaining to any forward-looking statement made by the Company. The Company does not intend to update, supplement, amend or revise any such forward-looking statement whether as a result of new information, future events or otherwise. Nothing in the Information shall be construed as a profit forecast.

The Information may include financial information that are not defined or recognized under the International Financial Reporting Standards (IFRS). These measures are derived from the Company's consolidated financial statements and provided as additional information to complement IFRS measures. Any financial information provided by the Company should not be considered in isolation or as a substitute for analysis of the Company's financial information as reported under the IFRS.

Consolidated Income Statement

SAR millions	2Q-2026	2Q-2025	YoY %	1H-2026	1H-2025	YoY %
Revenue	798.9	811.8	-1.6%	1,523.1	1,512.9	0.7%
Costs of revenue	(623.9)	(631.2)	-1.2%	(1,208.2)	(1,156.1)	4.5%
Gross profit	**175.0**	**180.6**	**-3.1%**	**314.9**	**356.8**	**-11.7%**
Gross profit margin	***21.9%***	***22.2%***	***-0.3pp***	***20.7%***	***23.6%***	***-2.9pp***
Other income	3.4	5.4	-37.1%	7.0	7.0	0.1%
General and administrative expenses	(80.4)	(76.5)	5.1%	(153.1)	(150.9)	1.5%
Selling and marketing expenses	(19.6)	(20.2)	-2.9%	(39.1)	(37.0)	5.5%
Long-term Incentive Plan	(1.2)	(1.5)	-20.7%	(2.3)	(3.8)	-38.1%
Impairment loss on receivables	(7.5)	(6.3)	20.0%	(13.0)	(13.4)	-2.9%
Operating profit	**69.7**	**81.6**	**-14.6%**	**114.3**	**158.6**	**-27.9%**
Operating Profit margin	***8.7%***	***10.1%***	***-1.3pp***	***7.5%***	***10.5%***	***-3.0pp***
Finance cost	(16.5)	(10.0)	64.7%	(33.7)	(19.9)	68.8%
Finance income	6.9	5.4	26.7%	13.4	13.1	2.3%
Profit before Zakat	**60.1**	**77.0**	**-22.0%**	**94.1**	**151.8**	**-38.0%**
Zakat	(5.9)	(8.8)	-32.9%	(13.8)	(16.3)	-15.3%
Profit after Zakat	**54.1**	**68.2**	**-20.6%**	**80.3**	**135.5**	**-40.7%**
Profit margin	***6.8%***	***8.4%***	***-1.6pp***	***5.3%***	***9.0%***	***-3.7pp***
Profit for the year attributable to:						
Shareholders' of the Company	**57.9**	**82.1**	**-29.5%**	**96.3**	**154.3**	**-37.6%**
Non-controlling interest	(3.8)	(14.0)	-72.8%	(16.0)	(18.8)	-14.7%
Additional information:						
EPS[1]	0.25	0.36	-29.5%	0.42	0.67	-37.6%
EBITDA	**122.7**	**129.1**	**-5.0%**	**219.2**	**250.2**	**-12.4%**
EBITDA margin	***15.4%***	***15.9%***	***-0.6pp***	***14.4%***	***16.5%***	***-2.1pp***

[1] *Earnings per share (EPS) is calculated based on attributable net profit and the weighted average number of shares which reads 230,000,000 shares as of 1H26, and 230,000,000 as of 1H25.*

Consolidated Balance Sheet

SAR millions	30-Jun -26	31-Dec -25
ASSETS		
Property and equipment	2,544.5	2,498.8
Right-of-use assets	594.7	492.2
Intangible assets and goodwill	548.1	547.6
Investment properties	0.4	0.4
Investments in associate	55.4	-
Financial asset at amortized cost	300.2	298.1
Prepayments and other non-current assets	24.1	22.2
Other long-term receivables	137.6	144.7
Non-current assets	**4,204.8**	**4,004.1**
Inventories	215.5	196.3
Accounts and other receivables	1,075.7	975.0
Contract assets	69.3	39.8
Prepayments and other current assets	162.4	174.4
Cash and cash equivalents	356.6	439.2
Current assets	**1,879.3**	**1,824.6**
TOTAL ASSETS	**6,084.2**	**5,828.7**
EQUITY		
Share capital	232.0	232.0
Treasury shares	(2.0)	(2.0)
Share premium	1,653.5	1,653.5
Profit/loss for the period	96.3	290.2
Retained earnings	1,215.0	998.4
Equity attributable to shareholders of the Company	**3,194.8**	**3,172.0**
Non-controlling interests	410.8	409.4
Total equity	**3,605.6**	**3,581.4**
LIABILITIES		
Long-term loans	331.0	334.0
Lease liabilities	573.6	481.2
Employees' end of service benefits	318.3	313.0
Non-current liabilities	**1,222.9**	**1,128.2**
Short-term loans	387.0	297.5
Current portion of long-term loans	8.0	-
Current portion of lease liabilities	70.9	63.7
Accounts payables	370.4	362.2
Accrued and other current liabilities	406.6	365.4
Accrued Zakat	12.7	30.3
Current liabilities	**1,255.6**	**1,119.1**
Total liabilities	**2,478.5**	**2,247.3**
TOTAL EQUITY AND LIABILITIES	**6,084.2**	**5,828.7**
Additional information:		
(Net Cash) Net Debt	69,248	(105,745)
Total debt (including leases)	713,737	439,079
Net Debt / Equity	0.019	(0.030)
Total Debt / Equity	0.198	0.123
12 months rolling EBITDA	465,317	496,326
Net Debt / EBITDA	0.149	(0.213)
Total Debt / EBITDA	1.53	0.88